@article {Rocco2020.10.21.20217208, author = {Patricia R. M. Rocco and Pedro L. Silva and Fernanda F. Cruz and Marco Antonio C. M. Junior and Paulo F. G. M. M. Tierno and Marcos A. Moura and Lu{\'\i}s Frederico G. De Oliveira and Cristiano C. Lima and Ezequiel A. Dos Santos and Walter F. Junior and Ana Paula S. M. Fernandes and Kleber G. Franchini and Erick Magri and Nara F. de Moraes and Jos{\'e} M{\'a}rio J. Gon{\c c}alves and Melanie N. Carbonieri and Ivonise S. Dos Santos and Nat{\'a}lia F. Paes and Paula V. M. Maciel and Raissa P. Rocha and Alex F. de Carvalho and Pedro Augusto Alves and Jos{\'e} Luiz P. Modena and Artur T. Cordeiro and Daniela B. B. Trivella and Rafael E. Marques and Ronir R. Luiz and Paolo Pelosi and Jose Roberto Lapa e Silva and on behalf of the SARITA-2 investigators}, title = {Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial}, elocation-id = {2020.10.21.20217208}, year = {2020}, doi = {10.1101/2020.10.21.20217208}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {The antiparasitic drug nitazoxanide is widely available and exerts broad-spectrum antiviral activity in vitro. However, there is no evidence of its impact on SARS-CoV-2 infection.In a multicenter, randomized, double-blind, placebo-controlled trial, adult patients who presented up to 3 days after onset of Covid-19 symptoms (dry cough, fever, and/or fatigue) were enrolled. After confirmation of SARS-CoV2 infection by RT-PCR on nasopharyngeal swab, patients were randomized 1:1 to receive either nitazoxanide (500 mg) or placebo, TID, for 5 days. The primary outcome was complete resolution of symptoms. Secondary outcomes were viral load, general laboratory tests, serum biomarkers of inflammation, and hospitalization rate. Adverse events were also assessed.From June 8 to August 20, 2020, 1,575 patients were screened. Of these, 392 (198 placebo, 194 nitazoxanide) were analyzed. Median time from symptom onset to first dose of study drug was 5 (4-5) days. At the 5-day study visit, symptom resolution did not differ between the nitazoxanide and placebo arms. However, at the 1-week follow-up, 78\% in the nitazoxanide arm and 57\% in the placebo arm reported complete resolution of symptoms (p=0.048). Swabs collected were negative for SARS-CoV-2 in 29.9\% of patients in the nitazoxanide arm versus 18.2\% in the placebo arm (p=0.009). Viral load was also reduced after nitazoxanide compared to placebo (p=0.006). No serious adverse events were observed.In patients with mild Covid-19, symptom resolution did not differ between the nitazoxanide and placebo groups after 5 days of therapy. However, early nitazoxanide therapy was safe and reduced viral load significantly.Take home message This was the first study to evaluate the effect of early nitazoxanide therapy in mild Covid-19. Nitazoxanide did not accelerate symptom resolution after 5 days of therapy; however, reduced viral load significantly with no serious adverse events.Competing Interest StatementDr. Rocco reports personal fees from SANOFI as a DSMB member. The other authors declare no competing interests.Clinical TrialNCT04552483Funding StatementSupported by the Brazilian Council for Scientific and Technological Development (CNPq), Brazilian Ministry of Science, Technology, and Innovation for Virus Network; Brasilia, Brazil, number: 403485/2020-7 and Funding Authority for Studies and Projects, Brasilia, Brazil, number: 01.20.0003.00.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB/oversight body was the Brazilian National Committee of Ethics in Research (CONEP), and the approval number is CAAE: 32258920.0.1001.5257. The study was further approved by local committees of ethics in research for the seven health units. The investigators have followed all appropriate research reporting guidelines. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe investigators plan on turning all individual participant data (IPD) available after the publication of the manuscript, with cautious of not sharing confidential data.}, URL = {https://www.medrxiv.org/content/early/2020/10/23/2020.10.21.20217208}, eprint = {https://www.medrxiv.org/content/early/2020/10/23/2020.10.21.20217208.full.pdf}, journal = {medRxiv} }